INTRODUCTION
Lamivudine, (2R-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, [1] is a synthetic nucleoside analogue with activity against the human immunodeficiency virus (HIV) and hepatitis B virus (HBV). [2] The molecule has two chiral centers and is manufactured as the pure 2R, cis(-)-enantiomer. The racemic mixture from which lamivudine originates has antiretroviral activity but is less potent and substantially more toxic than the pure (-)-enantiomer. Compared with the (+)-enantiomer, the phosphorylated (-)-enantiomer is more resistant to cleavage from nascent RNA/DNA duplexes and sophisticated instrumentation. [8] Lamivudine can also be determined by Reverse Phase-HPLC method with lesser runtime, but the aforementioned drawback still persists. [9] One of the first methods for visible spectrophotometric determination of lamivudine was based on the colored condensation products of aromatic aldehydes; [10] this method suffers from a drawback as the interference from the excipients is more since the determination is carried out at much shorter wavelengths. It is also reported that lamivudine can also be assayed by titrimetric methods based on diazocoupling, redox reaction using Folin-Ciocalteu reagent, and redox-complexation reaction using ferric chloride-orthophenanthroline. [11] However, the above mentioned titrimetric methods are reported to suffer from disadvantages like unstablity of the reagents, high cost of the chemicals, reduced sensitivity, etc. [12] The present research work describes a UV spectrophotometric method for estimation of lamivudine in API and its pharmaceutical preparation.
MATERIALS AND METHODS
Elico SL-159 UV-visible spectrophotometer equipped with a matched quartz cells ultrasonic bath was used to carry out the assay. The solvent used for the assay was spectroscopic-grade methanol.
Evaluation of wavelength
About 10 µg/mL of lamivudine drug substance was accurately prepared in spectroscopic-grade methanol solvent. This preparation was then scanned in the 200-350 nm UV region. The wavelength maxima (λ max ) was observed at 270 nm and this wavelength was adopted for absorbance measurement [ Figure 1 ].
Standard preparation
Accurately weighed 100 mg of lamivudine test standard was transferred to a volumetric flask containing 25 mL of methanol solvent. This was sonicated for about 5 min to dissolve it and the resultant solution was diluted to 100 mL with methanol solvent. Ten milliliters of this standard preparation was transferred to another volumetric flask and then diluted to 100 mL with methanol solvent.
Sample preparation
Ten tablets from the marketed sample were weighed and crushed uniformly with the help of a mortar and pestle. An accurately weighed powder sample equivalent to 100 mg of lamivudine was transferred into a volumetric flask containing 25 mL methanol solvent. The contents were sonicated for about 5 min so that the dissolution is enhanced and is completed in 15 min. Ten millititers of the supernatant solution was then taken and diluted to 100 mL with methanol solvent [ Table 1 ].
Procedure
The baseline correction on the UV spectrophotometer was performed using methanol as blank solvent in both reference and sample quartz cells. The aim was to obtain the absorbance of the standard (10 µg/mL of lamivudine) and sample preparations at 270 nm and determine the content of C 8 H 11 N 3 O 3 S in each tablet.
VALIDATION
The method was validated for specificity, linearity, accuracy, ruggedness, and solution stability.
Specificity:
The specificity of the method was established by measuring the interference, if any, observed due to the methanol solvent at the wavelength maxima of lamivudine. No significant absorbance due to methanol was observed at 270 nm [ Figure 1 ].
Linearity
The linearity of the method was established by determining the absorbance of different concentrations of lamivudine drug substance over a range of 50% (5 µg/mL) to 150% (15 µg/mL) of the normal sample preparation. Each level was measured in triplicate.
The calibration curve, as plot of absorbance vs concentration in µg/mL of lamivudine, was found to be rectilinear for 5, 8, 10, 12, and 15 µg/mL concentrations of lamivudine. The correlation coefficient was found to be more than 0.9998 [ Figure 2 ].
Precision
The assay of the same batch was performed in six replicates and the percentage relative standard deviation (%RSD) measured. The %RSD was found to be not more than 0.5%.
Accuracy
The accuracy of the method was established by adding the lamivudine test standard solution of the pre-analyzed tablet formulation. The analysis at each level was performed in triplicate and the mean recovery of lamivudine was measured. The percent recovery at each level was found to be well within the range of 98.0%-102.0%, indicating insignificant interference from the excipients.
Ruggedness
The ruggedness of the method was established by having the precision study performed on another instrument by another analyst. The cumulative %RSD for content of lamivudine for the samples of precision and ruggedness study were found to be not more than 1.0%.
Solution stability
The absorbance of the same sample solution at the initial stage and intervals of 4 hours, 8 hours, 12 hours, and 24 hours were measured and the cumulative %RSD determined. The %RSD was found to be not more than 2.0%
CONCLUSION
The proposed method for the assay of the popular antiretroviral agent lamivudine in the commercially available tablet formulation is simple, accurate, economical, and rapid. It can be easily adopted for routine quality control for monitoring the assay in the API, in-process samples, and the finished tablet formulation. The method can be extended for studying the dissolution profile.
